Medical News

RSS

FDA accepts proposed proprietary name Exelbine for ADVENTRX Pharmaceuticals' ANX-530

ADVENTRX Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted the proposed proprietary name "Exelbine™" for the Company's product candidate ANX-530 (vinorelbine injectable emulsion).

12 Mar 2010

Life insurance industry is for faster pace of change in the use of technology

The long-term outlook for the life insurance industry is for a faster pace of change, particularly in the use of technology. That was the conclusion of a survey of top industry executives by LOMA.

12 Mar 2010

Childhood obesity: Genetic variation could be a factor

Increasing childhood obesity has worried governments and public health advisers in many countries. But a study of 300 children with severe obesity by the University of Cambridge and the Wellcome Trust Sanger Institute, suggest the problem may be more complicated than simply bad diet, overeating, or lack of exercise.

12 Mar 2010

TaiGen Biotechnology's nemonoxacin Phase II study in DFI meets primary endpoints

TaiGen Biotechnology Co., Ltd. announced today the Phase II trial of nemonoxacin (TG-873870) in Diabetic Foot Infection (DFI) with once-a-day dosing met the primary endpoints and showed promising clinical efficacy and good tolerability.

12 Mar 2010

Antibiotics lower risk of developing gastric cancer

Helicobacter pylori, a bacterium found in about 50% of humans worldwide, can cause stomach ulcers and, in extreme cases, gastric cancer. In an article for F1000 Medicine Reports, Seiji Shiota and Yoshio Yamaoka discuss the possible eradication of H. pylori infections

12 Mar 2010

St. Jude Medical to exhibit cardiac clinical solution products portfolio at ACC 2010

St. Jude Medical, Inc. today announced it will display products and technologies from the company’s wide array of clinical solutions in the cardiology, cardiac surgery, atrial fibrillation and cardiac rhythm management markets at ACC 2010.

12 Mar 2010

$Bisphosphonate treatments may affect bone quality and increase risk of atypical fractures of femur$

Bisphosphonate treatments may affect bone quality and increase risk of atypical fractures of femur

Bisphosphonate treatments, proven to enhance bone density and reduce fracture incidence in post-menopausal women, may adversely affect bone quality and increase risk of atypical fractures of the femur when used for four or more years, according to preliminary research presented today at the 2010 Annual Meeting of the American Academy of Orthopaedic Surgeons.

12 Mar 2010

Genetix Pharmaceuticals announces completion of $35M Series B financing

Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today that it has completed a $35 million Series B financing with new investors Third Rock Ventures and Genzyme Ventures joining TVM Capital, Forbion and Easton Capital. Proceeds from the financing will be used to advance current clinical programs, strengthen platform capabilities and further expand the team.

12 Mar 2010

Pregnancy-related deaths increase in Michigan, Amnesty International report

In releasing a new report on maternal health nationwide, Amnesty International today revealed that flaws and shocking disparities in maternal health care that the government is ignoring lead to two to three women dying daily in the United States from pregnancy-related complications, with half of these deaths believed preventable, according to the Centers for Disease Control. A state-by-state examination shows that Michigan is 42nd on a maternal mortality ranking, with 13.6 deaths per 100,000 live births.

12 Mar 2010

Pro-Pharmaceuticals reports net loss applicable to common stock of $1.3M for fourth-quarter 2009

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today reported its financial results for full year and fourth quarter, ended December 31, 2009. These results are included in the Company’s Annual Report on Form 10-K which has been filed with the SEC.

12 Mar 2010

GTC Biotherapeutics reports total net loss of $1.7M for fourth-quarter 2009

GTC Biotherapeutics, Inc. today reported its financial results for the fourth quarter and fiscal year ended January 3, 2010. The total net loss for the fourth quarter was $1.7 million, or $0.09 per share, compared with $6.2 million, or $0.60 per share, for the fourth quarter of 2008. The total net loss for 2009 was $27.9 million, or $2.18 per share, compared to $22.7 million, or $2.31 per share, for 2008.

12 Mar 2010

Verisk Health upgrades Explorer product line to improve organization’s exposure to healthcare risk

Verisk Health, Inc., a global leader in healthcare data analytics and risk management, today announced several upgrades to its Explorer product line, including functionality that allows users to evaluate the impact of a member’s lifestyle behaviors on an organization’s overall healthcare and utilization costs.

12 Mar 2010

Manhattan Pharmaceuticals to merge with Ariston Pharmaceuticals

Manhattan Pharmaceuticals, Inc. today announced it has entered into a definitive agreement and plan of merger and completed the merger transaction with Ariston Pharmaceuticals, Inc., a privately-held, specialty pharmaceutical company. As a result of the merger, Ariston became a wholly owned subsidiary of Manhattan Pharmaceuticals.

12 Mar 2010

UNICEF Tap Project raises funds to help provide clean water to millions of children around the world

Now in its fourth year, the UNICEF Tap Project, a grassroots initiative from the U.S. Fund for UNICEF, returns to cities nationwide during World Water Week 2010 (March 21-27). The UNICEF Tap Project invites individuals to donate $1 or more for tap water at participating restaurants or online at tapproject.org to provide clean water to children around the world.

12 Mar 2010

California ranks 35th in maternal mortality, records 11.3 deaths per 100,000 live births

In releasing a new report on maternal health nationwide, Amnesty International today revealed that flaws and shocking disparities in maternal health care that the government is ignoring lead to two to three women dying daily in the United States from pregnancy-related complications, with half of these deaths believed preventable, according to the Centers for Disease Control. A state-by-state examination shows that California is 35th on a maternal mortality ranking, with 11.3 deaths per 100,000 live births.

12 Mar 2010

Prevention of choking hazards in food: Safe, children oriented packaging and design needed

While choking hazards in toys have been widely publicized and addressed by the Consumer Product Safety Commission (CPSC), ironically choking hazards in food have lacked federal attention despite the fact that food is far more likely to go into a child’s mouth.

12 Mar 2010

Halozyme Therapeutics reports net loss of $12.7M for fourth-quarter of 2009

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the fourth quarter and year ended December 31, 2009.

12 Mar 2010

Vial of Life organizer helps family and medical staff find prescriptions, insurance information fast

When every second counts, help family and medical staff find prescriptions and insurance information FAST! -- Use a "Vial of Life" organizer.

12 Mar 2010

Arena Pharmaceuticals reports lower net loss allocable to common stockholders in fourth-quarter 2009

Arena Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2009.

12 Mar 2010

Vertos Medical announces positive results from IRB I Patient Outcomes Trial of 'mild' for LSS

Medical device company Vertos Medical Inc. has announced the release of positive results from its U.S. IRB I Patient Outcomes Trial, a prospective, investigational review board-approved, 75-patient study of mild for the treatment of lumbar spinal stenosis (LSS). Six-week clinical data have shown that patients treated with mild experience statistically and clinically significant improvement in both pain and functional ability. The data also confirmed mild’s safety, with no reports of patient complications related to the procedure or the devices.

12 Mar 2010

Medical News

FDA accepts proposed proprietary name Exelbine for ADVENTRX Pharmaceuticals' ANX-530

Life insurance industry is for faster pace of change in the use of technology

Childhood obesity: Genetic variation could be a factor

TaiGen Biotechnology's nemonoxacin Phase II study in DFI meets primary endpoints

Antibiotics lower risk of developing gastric cancer

St. Jude Medical to exhibit cardiac clinical solution products portfolio at ACC 2010

Bisphosphonate treatments may affect bone quality and increase risk of atypical fractures of femur

Genetix Pharmaceuticals announces completion of $35M Series B financing

Pregnancy-related deaths increase in Michigan, Amnesty International report

Pro-Pharmaceuticals reports net loss applicable to common stock of $1.3M for fourth-quarter 2009

GTC Biotherapeutics reports total net loss of $1.7M for fourth-quarter 2009

Verisk Health upgrades Explorer product line to improve organization’s exposure to healthcare risk

Manhattan Pharmaceuticals to merge with Ariston Pharmaceuticals

UNICEF Tap Project raises funds to help provide clean water to millions of children around the world

California ranks 35th in maternal mortality, records 11.3 deaths per 100,000 live births

Prevention of choking hazards in food: Safe, children oriented packaging and design needed

Halozyme Therapeutics reports net loss of $12.7M for fourth-quarter of 2009

Vial of Life organizer helps family and medical staff find prescriptions, insurance information fast

Arena Pharmaceuticals reports lower net loss allocable to common stockholders in fourth-quarter 2009

Vertos Medical announces positive results from IRB I Patient Outcomes Trial of 'mild' for LSS

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News